Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
4
×
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
4
×
celgene
4
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
nash
pfizer
aducanumab
bayer
clinical trials
deals
genentech
intercept pharmaceuticals
johnson & johnson
ngm biopharmaceuticals
nonalcoholic steatohepatitis
What
bio
drug
4
×
roundup
4
×
news
approved
biogen
disease
liver
nash
race
week
adu
aducanumab
advanced
alnylam’s
alzheimer’s
amyloid
angst
approval
bagged
beats
bff
bids
billions
biogen’s
brammer
companies
complicated
conference
deals
depression
devoted
digital
dire
easl
effects
epidemic
failure
fatty
fda
Language
Current search:
roundup
×
drug
×
" boston blog main "
×
celgene
×
" bristol-myers squibb "
×
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More